These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 9588734)

  • 1. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
    Mok CC; Lau CS; Wong RW
    Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian failure and flares of systemic lupus erythematosus.
    Mok CC; Wong RW; Lau CS
    Arthritis Rheum; 1999 Jun; 42(6):1274-80. PubMed ID: 10366122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk factors of ovarian failure in the patients with systemic lupus erythematosus receiving cyclophosphamide therapy].
    Yang XY; Zhu X; Liang LQ; Zhan ZP; Ye YJ
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):960-2. PubMed ID: 16061002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
    Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
    Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
    Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
    J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
    Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
    Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.
    Mok CC; Ying KY; Ng WL; Lee KW; To CH; Lau CS; Wong RW; Au TC
    Am J Med; 2006 Apr; 119(4):355.e25-33. PubMed ID: 16564783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus.
    Ioannidis JP; Katsifis GE; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2002 Oct; 29(10):2129-35. PubMed ID: 12375322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
    Manger K; Wildt L; Kalden JR; Manger B
    Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of antiphospholipid antibodies following cyclophosphamide therapy in patients with systemic lupus erythematosus.
    Vlachoyiannopoulos PG; Toya SP; Katsifis G; Zintzaras E; Tzioufas AG; Moutsopoulos HM
    J Rheumatol; 2008 Sep; 35(9):1768-75. PubMed ID: 18634157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide boluses induce micronuclei expression in buccal mucosa cells of patients with systemic lupus erythematosus independent of cytochrome P450 2D6 status.
    Aceves Avila FJ; Esquivel Nava GA; Gallegos Arreola MP; Gómez Meda B; Zúñiga González G; Ramos-Remus C
    J Rheumatol; 2004 Jul; 31(7):1335-9. PubMed ID: 15229952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
    Mok CC; Chan PT; To CH
    Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
    Singh G; Saxena N; Aggarwal A; Misra R
    J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis.
    Takada K; Arefayene M; Desta Z; Yarboro CH; Boumpas DT; Balow JE; Flockhart DA; Illei GG
    Arthritis Rheum; 2004 Jul; 50(7):2202-10. PubMed ID: 15248218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
    Mok CC; Ying KY; Tang S; Leung CY; Lee KW; Ng WL; Wong RW; Lau CS
    Arthritis Rheum; 2004 Aug; 50(8):2559-68. PubMed ID: 15334470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
    Laskari K; Zintzaras E; Tzioufas AG
    Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients.
    Faurschou M; Sorensen IJ; Mellemkjaer L; Loft AG; Thomsen BS; Tvede N; Baslund B
    J Rheumatol; 2008 Jan; 35(1):100-5. PubMed ID: 17937462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
    Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
    J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brief Report: The Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti-Müllerian Hormone.
    Tamirou F; Husson SN; Gruson D; Debiève F; Lauwerys BR; Houssiau FA
    Arthritis Rheumatol; 2017 Jun; 69(6):1267-1271. PubMed ID: 28235250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.